Gallbladder cancer (GBC) is rare in Europe, the United States, and Canada. However, in some areas of South America, particularly in the Andean region of Chile, Ecuador, Peru, and Bolivia, the incidence and mortality rate are high.
The Extended Education Session “Management of Complex Upper Gastrointestinal Cases: Implementation of Best Evidence,” to be held on June 2, will address these and other questions facing oncologists specializing in upper GI cancers.
The guideline, organized into 21 recommendations of how to use molecular biomarkers to diagnose and treat patients with colorectal cancer, represented an unprecedented collaboration between four organizations: CAP, ASCP, the Association for Molecular Pathology, and ASCO.
Patients with potentially curable pancreatic cancer should be treated with two medications—gemcitabine and capecitabine—after tumor resection, as long as there are no concerns about toxicity and chemotherapy.
Phase III trial CALGB 80802 failed to demonstrate OS benefit with addition of doxorubicin to sorafenib in the first-line treatment of advanced HCC. The results contradict earlier phase II data, and suggest that the role of chemotherapy in advanced HCC could come to an end.
The benefits of palliative care for patients with advanced cancer and short life expectancy has been well established. New research suggests this care could improve quality of life and mood both among patients with lung and GI cancers early in the course of disease and their caregivers.
This Education Session offers insight into how past failures in gastric cancer, along with emerging genetic and molecular information, hold good solutions to solving the current treatment conundrum for this disease.
Drs. Cinar and Picozzi summarize the history of pancreatic cancer treatment options, the challenges associated with treatment and recurrence prevention, and the emerging adjuvant options being studied in current ongoing trials.